Form 8-K

8-K — Neuphoria Therapeutics Inc.

Accession: 0001213900-26-111863

Filed: 2026-10-23

Period: 2026-10-23

CIK: 0001191070

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Material Modifications to Rights of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — ea0309146-8k_neuphoria.htm (Primary)

EX-4.2 — AMENDMENT NO. 1 TO RIGHTS AGREEMENT, DATED AS OF OCTOBER 23, 2026, BY AND BETWEEN NEUPHORIA THERAPEUTICS INC. AND COMPUTERSHARE TRUST COMPANY, N.A., AS RIGHTS AGENT (ea030914601ex4-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0309146-8k_neuphoria.htm · Sequence: 1

false

0001191070

2026-10-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

FORM

8-K

CURRENT

REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date

of earliest event reported): October 23, 2026

Neuphoria Therapeutics

Inc.

(Exact name of Registrant

as Specified in its Charter)

Delaware

(State Or Other Jurisdiction

of Incorporation)

001-41157

99-3845449

(Commission File Number)

(I.R.S. Employer

Identification No.)

14 Milliston Road, Box 195, Millis, Massachusetts

02054

(Address of Principal Executive Offices)

(Zip Code)

(339) 240-6066

Registrant’s Telephone

Number, Including Area Code

Securities registered pursuant to Section

12(b) of the Act

Title of Each Class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.00001 par value per share

NEUP

The Nasdaq Stock Market, LLC

Check the appropriate

box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions (see General Instruction A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act

Indicate by check mark

whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule

12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth

company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive

Agreement.

On October 23, 2026,

the Board of Directors (the “Board”) of Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”),

a Delaware corporation, entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as of October 27, 2025,

by and between the Company and Computershare Trust Company, N.A., as Rights Agent (the “Original Rights Agreement,” and as

amended by the Amendment). Pursuant to the Amendment, the Final Expiration Date of the Original Rights Agreement has been extended until

the Close of Business on October 27, 2027, unless earlier extended, modified or terminated. Capitalized terms used but not defined herein

have the meanings specified in the Rights Agreement, as amended.

The Rights are in all

respects subject to and governed by the provisions of the Original Rights Agreement, except as as amended by the Amendment. The above

description of the Original Rights Agreement and the Amendment does not purport to be complete and is qualified in its entirety by reference

to the full text of the Original Rights Agreement, which is incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company

with the U.S. Securities and Exchange Commission on October 27, 2025, and to the Amendment, which is attached hereto as Exhibit 4.2, both

of which are incorporated herein by reference.

Item 3.03. Material

Modifications to Rights of Security Holders.

The information set forth

under Item 1.01 is incorporated into this Item 3.03 by reference.

Item 9.01 Financial

Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

4.1

Rights Agreement, dated as of October 27, 2025 between Neuphoria Therapeutics Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B (incorporated herein by reference to Exhibit 4.1 to Form 8-K filed with the SEC on October 27, 2025)

4.2

Amendment No. 1 to Rights Agreement, dated as of October 23, 2026, by and between Neuphoria Therapeutics Inc. and Computershare Trust Company, N.A., as rights agent

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATUREs

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned, thereunto duly authorized.

NEUPHORIA THERAPEUTICS INC.

By:

/s/ Spyridon Papapetropoulos

Spyridon Papapetropoulos

Interim Chief Executive Officer

Date: October 23, 2026

EX-4.2 — AMENDMENT NO. 1 TO RIGHTS AGREEMENT, DATED AS OF OCTOBER 23, 2026, BY AND BETWEEN NEUPHORIA THERAPEUTICS INC. AND COMPUTERSHARE TRUST COMPANY, N.A., AS RIGHTS AGENT

EX-4.2

Filename: ea030914601ex4-2.htm · Sequence: 2

Exhibit 4.2

AMENDMENT

NO. 1 TO RIGHTS AGREEMENT

This

Amendment No. 1, dated as of October 23, 2026 (this “Amendment”), amends that certain Rights Agreement, dated

as of October 27, 2025 (the “Rights Agreement”), by and between Neuphoria Therapeutics Inc., a Delaware corporation

(the “Company”), and Computershare Trust Company, N.A. (the “Rights Agent”). Capitalized terms used

herein and not otherwise defined shall have the meanings ascribed to such terms in the Rights Agreement.

WHEREAS,

the Company and the Rights Agent have executed and entered into the Rights Agreement;

WHEREAS,

Section 27 of the Rights Agreement provides, among other things, that the Company may, in its sole and absolute discretion, and the Rights

Agent shall, if the Company so directs, supplement or amend any provision of the Rights Agreement in any respect without the approval

of any holders of Rights or Common Shares, and the Rights Agent shall, if the Company so directs, execute such supplement or amendment;

WHEREAS,

to the knowledge of the Company, as of the date hereof, the Rights are still redeemable;

WHEREAS,

the Board of Directors of the Company has: (i) deemed it advisable and in the best interests of the Company and its stockholders to amend

certain provisions of the Rights Agreement as set forth herein; (ii) approved this Amendment; and (iii) authorized the proper officers

of the Company to execute and deliver the same to the Rights Agent;

WHEREAS,

pursuant to and in accordance with Section 27 of the Rights Agreement, the Company desires to amend the Rights Agreement as set forth

below.

NOW,

THEREFORE, in consideration of the premises set forth above, the parties hereto, intending to be legally bound hereby, agree as follows:

1. The definition of “Final

Expiration Date” set forth in Section 1(w) of the Rights Agreement is hereby amended and restated in its entirety as follows:

““Final

Expiration Date” shall mean the Close of Business on October 27, 2027.”

2. Exhibit B to the Rights

Agreement shall be deemed amended in a manner consistent with this Amendment.

3. This Amendment shall

be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance

with the laws of such State applicable to contracts to be made and performed entirely within such State, without giving effect to the

choice of law or conflict of law principles thereof or of any other jurisdiction to the extent that such principles would require or

permit the application of the laws of another jurisdiction.

4. If any term, provision,

covenant, or restriction of this Amendment, or the application thereof to any circumstance, is held by a court of competent jurisdiction

or other authority to be invalid, null, void, or unenforceable, the remainder of the terms, provisions, covenants, and restrictions of

this Amendment shall remain in full force and effect and shall in no way be affected, impaired, or invalidated.

5. Except as expressly

set forth in this Amendment, the Rights Agreement will not otherwise be supplemented or amended by virtue of this Amendment and will

remain in full force and effect and otherwise shall be unaffected by virtue of this Amendment.

6. This Amendment may be

executed in any number of counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such

counterparts shall together constitute but one and the same instrument. A signature to this Amendment executed and/or transmitted electronically

shall have the same authority, effect, and enforceability as an original signature.

7. This Amendment shall

be effective as of the date first written above.

8. Upon and after the effectiveness

of this Amendment, each reference in the Rights Agreement to “this Agreement,” “hereunder,” “hereof”

or words of like import referring to the Rights Agreement, and each reference in any other document to “the Rights Agreement,”

“thereunder,” “thereof” or words of like import referring to the Rights Agreement, shall mean and be a reference

to the Rights Agreement as amended hereby.

9. The undersigned officer

of the Company, being duly authorized on behalf of the Company, hereby certifies in his or her capacity as an officer on behalf of the

Company to the Rights Agent that this Amendment is in compliance with the terms of Section 27 of the Rights Agreement.

[Signature

Page Follows]

IN WITNESS WHEREOF,

this Amendment has been duly executed by the Company and the Rights Agent as of the date first written above.

NEUPHORIA

THERAPEUTICS INC.

By:

/s/ Spyridon Papapetropoulos

Name:

Spyridon Papapetropoulos

Title:

Interim CEO

COMPUTERSHARE

TRUST COMPANY, N.A.

By:

/s/ Shirley Nessralla

Name:

Shirley Nessralla

Title:

Senior Vice President

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 23, 2026

Entity File Number

001-41157

Entity Registrant Name

Neuphoria Therapeutics

Inc.

Entity Central Index Key

0001191070

Entity Tax Identification Number

99-3845449

Entity Incorporation, State or Country Code

Entity Address, Address Line One

14 Milliston Road

Entity Address, Address Line Two

Box 195

Entity Address, City or Town

Millis

Entity Address, State or Province

Entity Address, Postal Zip Code

02054

City Area Code

339

Local Phone Number

240-6066

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.00001 par value per share

Trading Symbol

NEUP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration